Kristen Ambrose - 01 Feb 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
SVP & Chief Accounting Officer
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
01 Feb 2023
Net transactions value
$0
Form type
4
Filing time
03 Feb 2023, 15:32:27 UTC
Previous filing
27 Apr 2022
Next filing
28 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Award $0 +2,566 +73% $0.000000 6,062 01 Feb 2023 Direct F1
transaction VRTX Common Stock Award $0 +2,950 +49% $0.000000 9,012 01 Feb 2023 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest in installments beginning on 02/24/2023.
F2 Restricted stock unit award that vests in installments beginning on 02/10/2024.